Janney Montgomery Scott’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-1,312
Closed -$27K 2599
2022
Q3
$27K Hold
1,312
﹤0.01% 2468
2022
Q2
$29K Sell
1,312
-125
-9% -$3.52K ﹤0.01% 2295
2022
Q1
$62K Hold
1,437
﹤0.01% 2206
2021
Q4
$86K Sell
1,437
-16
-1% -$1.28K ﹤0.01% 2324
2021
Q3
$125K Buy
1,453
+83
+6% +$8.33K ﹤0.01% 2222
2021
Q2
$152K Sell
1,370
-83
-6% -$7.97K ﹤0.01% 2176
2021
Q1
$162K Buy
1,453
+45
+3% +$5.92K ﹤0.01% 2084
2020
Q4
$150K Buy
1,408
+13
+0.9% +$1.73K ﹤0.01% 2140
2020
Q3
$194K Sell
1,395
-30
-2% -$6.26K ﹤0.01% 1919
2020
Q2
$461K Buy
+1,425
New +$229K ﹤0.01% 1408
2016
Q2
Sell
-1,125
Closed -$118K 929
2016
Q1
$118K Sell
1,125
-146
-11% -$11.3K ﹤0.01% 1211
2015
Q4
$102K Hold
1,271
﹤0.01% 1312
2015
Q3
$88K Sell
1,271
-417
-25% -$36.3K ﹤0.01% 1344
2015
Q2
$165K Buy
+1,688
New +$180K ﹤0.01% 1860
2014
Q4
Sell
-938
Closed -$111K 2365
2014
Q3
$111K Sell
938
-125
-12% -$15.6K ﹤0.01% 2163
2014
Q2
$138K Buy
1,063
+334
+46% +$39.4K ﹤0.01% 2065
2014
Q1
$117K Buy
729
+437
+150% +$62.7K ﹤0.01% 1922
2013
Q4
$40.6K Buy
+292
New +$29.2K ﹤0.01% 1975

Other funds holding INO

Janney Montgomery Scott's INO Position: Q4 2022 in Review

Janney Montgomery Scott sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 1,312 shares — an estimated $27K sold.

Janney Montgomery Scott first reported a position in INO in Q4 2013 and held it in 18 quarters. The position peaked at $461K in Q2 2020. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

  • Janney Montgomery Scott reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Janney Montgomery Scott sold 1,312 Inovio Pharmaceuticals shares in Q4 2022, an estimated $27K.
  • Janney Montgomery Scott first reported a position in Inovio Pharmaceuticals in Q4 2013 and held it in 18 quarters.
  • Janney Montgomery Scott's Inovio Pharmaceuticals position peaked at $461K in Q2 2020.
  • 183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Janney Montgomery Scott's 13F filing for Q4 2022, filed 1 Feb 2023.